In view of these findings, the patient was discussed at a multidisciplinary consultation meeting, and a decision was taken to opt for neoadjuvant chemotherapy of the cisplatin-etoposide type for large-cell bladder neuroendocrine carcinoma, and hormone therapy with luteinizing hormone-releasing hormone (LH-RH) analogs for prostatic adenocarcinoma. Here, GNRH1 is linked to prostate adenocarcinoma.